Vericel Q4 revenue rises 23%, beats estimates

Vericel

26/02/2026 13:03

Overview

Advanced therapies company's Q4 revenue rose 23%, beating analyst expectations

Net income for Q4 increased 17% yr/yr

Company achieved record Q4 gross margin of 79%

Outlook

Vericel forecasts 2026 total revenue between $316 mln and $326 mln

Company expects MACI revenue of $280 mln to $286 mln in 2026

Vericel anticipates gross margin of approximately 75% for 2026

Result Drivers

MACI REVENUE GROWTH - MACI revenue grew 23% in Q4, contributing significantly to total revenue growth

SALES FORCE EXPANSION - Completed MACI sales force expansion, contributing to increased revenue

FACILITY COSTS - Increased operating expenses due to new Burlington facility costs

Company press release: ID:nGNX4Wkb8x

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$92.92 mln
$91.12 mln (7 Analysts)
Q4 EPS
$0.45
Q4 Net Income
$23.24 mln
Q4 Adjusted EBITDA
$37.30 mln
Q4 Gross Margin
79.00%
Q4 Adjusted EBITDA Margin
40.00%
Q4 Gross Profit
$73.13 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vericel Corp is $56.50, about 52.3% above its February 25 closing price of $37.09

The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 63 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)